Back

Hospitalization-related costs among patients with atrial fibrillation treated with the factor Xa inhibitor edoxaban vs warfarin: results from the ENGAGE AF-TIMI 48 trial

30 August 2016 (10:25 - 10:35)
Organised by:
Congress Presentation Part of: Antithrombotic therapy in atrial fibrillation 2 Atrial fibrillation (AF) ESC Premium Access ESC Congress 2016

About the speaker

Photo
Professor Elizabeth A Magnuson

Saint Luke's Hospital, Kansas City (United States of America)

4 More presentations in this session

Presentation thumbnail
Validation of a Modified CHA2DS2-VASc score for stroke risk Stratification in Asian patients with qtrial fibrillation
Doctor T. Chao (Taipei, TW)
Abstract
Presentation thumbnail
Temporal change of anticoagulation therapy and its outcomes of Japanese atrial fibrillation patients in the real-world clinical practice: the Fushimi AF Registry.
Doctor M. Akao (Kyoto, JP)
Abstract Slides
Presentation thumbnail
Vitamin K antagonist control for patients with nonvalvular atrial fibrillation in Eastern and Southeastern Asia: an analysis of event rates from GARFIELD-AF
Professor S. Goto (Isehara, JP)
Abstract Slides
Presentation thumbnail
Reversal strategies and outcomes of major bleeding associated with direct oral anticoagulants compared to warfarin in routine practice: interim results from a multi-centre all-comer cohort
Mr Y. Xu (Toronto, CA)
Abstract Slides

Access the full session

Session thumbnail
Antithrombotic therapy in atrial fibrillation 2

The Event

Event poster

ESC Congress 2016

30 August 2016 10:25 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources